An old drug finds new purpose against retinal neovascularization

September 12, 2018, Sanford Burnham Prebys Medical Discovery Institute
Layton Smith, Ph.D. Credit: Sanford Burnham Prebys Medical Discovery Institute (SBP)

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have found that the anti-malaria drug amodiaquine inhibits the apelin receptor protein, which helps drive the vascularization behind diabetic retinopathy, wet age-related macular degeneration (AMD) and other conditions. Because the drug has been approved to treat malaria for decades, it could move relatively quickly through the pipeline to help patients. The study was published in the journal PLOS ONE.

"We have a receptor that has no relationship to the malarial bug— - it just happens that this compound interacts with the receptor and turns it off," says associate professor Layton Smith, Ph.D., director, Drug Discovery Florida, and senior author of the paper. "This could be an enormous benefit. Wet AMD is the leading cause of blindness in the Western world, affecting millions of people."

Wet AMD, and similar conditions, are often treated with drugs that inhibit the VEGF protein, which promotes angiogenesis or . These drugs can preserve sight, but do not work for all patients.

"They're great drugs, if you respond to them," says Smith. "But 30 percent of patients don't respond at all. Over time, many people lose their responsivity."

While using high-throughput chemical screening to identify compounds that boost apelin activity, Smith and colleagues were intrigued to find several that prevented the protein from activating the APJ receptor, a critical link in the apelin pathway.

The team knew apelin plays a role in embryonic blood vessel development. Unfortunately, the protein can be mistakenly turned on to cause aberrant vessel growth in adulthood. As a result, finding a good apelin inhibitor could be quite useful. One molecule that proved especially effective against apelin was amodiaquine, which has been used for decades to prevent malaria.

"People take amodiaquine around the world for malarial prophylaxis," says Smith. "It was an interesting idea that we could come up with a new, non-VEGF- based therapy for these eye diseases."

In the study, amodiaquine suppressed through both the apelin and VEGF pathways. In addition, the compound reversed vascular eye damage in animal models. Further study showed the compound blocked the receptor's function in a unique way: Instead of occupying the site to which apelin binds to activate the receptor, amodiaquine binds to another area, likely changing its conformation and thus inhibiting apelin's ability to turn it on and drive blood vessel growth.

One of the advantages of re-tasking an existing is that its safety profile is already established. Amodiaquine is well- tolerated, though it does cause liver toxicity over time. Smith believes this may not be a problem when treating eye disease, as the compound could be administered exclusively in the eye rather than being given systemically.

Because the drug is so well known, it could potentially take a streamlined path to patients. Since safety tests have already been done, a drug company would only have to prove its efficacy.

In addition to studying the existing drug, chemists on the team tweaked the amodiaquine molecule to make it even more effective. However, because these alterations created a distinct compound, any trial sponsors would have to prove its safety, extending the regulatory process.

Amodiaquine could be used by itself, but Smith and his team are curious to see if it works with existing anti-VEGF treatments.

"We want to know if there's synergy," says Smith. "These VEGF inhibitors are quite expensive, but we might be able to use less of them in combination with amodiaquine, or a similar small molecule, which are inexpensive by comparison."

Explore further: Discovery of novel mechanism for blood vessel formation suggests new vascular therapies

Related Stories

Discovery of novel mechanism for blood vessel formation suggests new vascular therapies

August 25, 2015
An international team of researchers, including scientists at A*STAR's Institute of Medical Biology (IMB), has shed new light on how the circulatory system and blood vessels are formed in the embryo. The discovery lays the ...

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Understanding the APJ Receptor Binding Site

June 1, 2010
( -- Apelin is a recently discovered peptide that binds to the apelin (or APJ) G-protein-coupled receptor. Apelin-13 (NH2-QRPRLSHKGPMPF-COOH), one of several cleavage products of the proprotein form of the apelin ...

Protein influence on early heart development could lead to better regenerative therapies

April 5, 2017
Stem cell therapies could one day help repair heart tissue in people with cardiovascular disease. But before doctors feel confident enough to transplant these potent cells into patients, they need to better understand how ...

Research suggests ELABELA hormone plays a key role in endoderm and heart development

April 23, 2014
The binding of hormones to their receptors plays a key role in the development of many organs of the body. The apelin receptor is expressed in the developing embryo, coming online many hours prior to its presently known ligand, ...

New class of drug targets heart disease

September 17, 2013
(Edmonton) Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

Recommended for you

Synthetic DNA-delivered antibodies protect against Ebola in preclinical studies

November 13, 2018
Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published ...

Scientists illuminate causes of hepatitis B virus-associated acute liver failure

November 13, 2018
National Institutes of Health scientists and their collaborators found that hepatitis B virus (HBV)-associated acute liver failure (ALF)—a rare condition that can turn fatal within days without liver transplantation—results ...

New strategy discovered toward possible prevention of cancers tied to mono, the 'kissing disease'

November 12, 2018
Researchers from the University of Minnesota, the Howard Hughes Medical Institute, and the University of Toronto have discovered a possible path forward in preventing the development of cancers tied to two viruses, including ...

Combination therapy promising against blindness-causing bacterial keratitis

November 12, 2018
Multidrug-resistant bacterial infections of the cornea are a leading cause of blindness and cannot be effectively managed with current ophthalmic antibiotics. A team of investigators has now devised a combination therapy ...

Hepatitis C treatment can be shortened in 50 percent of patients, study finds

November 12, 2018
Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient.

Salmonella found to be resistant to different classes of antibiotics

November 12, 2018
Brazil's Ministry of Health received reports of 11,524 outbreaks of foodborne diseases between 2000 and 2015, with 219,909 individuals falling sick and 167 dying from such diseases. Bacteria caused most outbreaks of such ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.